Cardiac rejuvenation therapy: Transcriptional co-activator with PDZ-binding motif (TAZ) suppresses tumor suppressor INK4a/p16 expression, and inhibits dilated cardiomyopathy and heart failure via up regulation of its target gene, 10/January/2017, 9.43 pm

Cardiac rejuvenation therapy: Oncofetal H19 RNA suppresses tumor suppressor INK4a/p16 expression, and inhibits dilated cardiomyopathy and heart failure via up regulation of its target gene, 9/January/2017, 11.12 pm
January 9, 2017
Natural product-derived therapy for Metastatic human tumors: Kukoamine A (KuA), a spermine alkaloid derived from Cortex lycii radicis and Lycium chinense among others, decreases the expression of c-Src protein, inhibits the expression of a number of enzymes of glycolysis, and suppresses proliferation, migration, invasion, tumorigenesis and metastasis via up regulation of its target gene, 10/January/2017, 11.20 pm
January 10, 2017
Show all

Introduction: What they say

A recent study from the Stem Cell Aging Group, Centro Nacional de Investigaciones Cardiovasculares, E-28029 Madrid, Spain shows that “Bmi1 limits dilated cardiomyopathy and heart failure by inhibiting cardiac senescence.” This study was published in the online journal 9 March 2015 issue of  Nature Communications by Prof Gonzalez, Gonzalez-Valdes and others.


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Cardiac rejuvenation therapy: Transcriptional co-activator with  PDZ-binding motif (TAZ) suppresses tumor suppressor INK4a/p16 expression, and inhibits dilated cardiomyopathy  and heart failure via up regulation of its target gene


From the Significance of the study to Public health relevance:

Given that: (1) cardiovascular disease is the leading cause of death worldwide; (2) Dilated cardiomyopathy is the leading cause of Heart failure; (3) the raise  of death rate, due to cardiovascular disease, has increased from 12.3 million in 1990 to 17.3 million in 2013; (4) 13% of cardiovascular disease occur due to  uncontrolled high blood pressure; (5) in India, in 2004, 14.6 lakhs deaths (14% of total deaths) were due to ischemic heart disease; (6) 85% of people over  80 years are susceptible to cardiovascular diseases; (7) the global economic cost spent in the treatment of cardiovascular disease in 2011 was little more than 10 billion US dollars; (8) the death due to cardiovascular disease is higher in low-to-middle income countries compared to developed countries; and (9) an alarming number of people, such as 230 lakhs people, will die from cardiovascular diseases each year by 2030, there is an urgent need to find:  (i) a cure to diseases, as mentioned above, leading to cardiovascular disease; (ii) a way to induce regeneration of adult cardiomyocytes that were lost in Myocardial patients; (iii) a cheaper alternative to the existing expensive drugs; and (iv) a side-effect-free Natural product-based drug.


From research findings to therapeutic opportunity:

This study suggests, for the first time, that TAZ, by increasing the expression of its target gene, it may suppress the expression of tumor suppressor  and the ageing marker INK4a/p16 (figure 1).

price-100[easy_payment currency=”USD”]

Thereby, it may: (1) inhibit cardiac senescence; (2) increase of regenerative potential in aged tissues; and (3) improve ventricular dimensions and contractility. Thus, (1) by treating myocardial patients with TAZ activators, one may prevent Dilated  cardiomyopathy and ageing-associated (or, stress-associated) decline in cardiac function; and (2) pharmacological formulations encompassing  “TAZ activators or TAZ activators plus any of the known drugs that inhibit cardiomyopathy may be used to inhibit dilated cardiomyopathy and heart failure (figure 1).

taz-suppresses-ink4a

Figure 1. Mechanistic insight into how TAZ activators may function as cardioprotective agents. TAZ inhibits dilated cardiomyopathy and heart failure via down regulation of ageing/senescence marker INK4a


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How TAZ suppresses the expression of tumor suppressor INK4a/p16.

# Research cooperation

Amount: $100

For purchase and payment details, you may reach us at admin@genomediscovery.org


References:

Web: http://genomediscovery.org or newbioideas.com

Citation: Boominathan, L., Cardiac rejuvenation therapy: Transcriptional co-activator with  PDZ-binding motif (TAZ) suppresses tumor suppressor INK4a/p16 expression, and inhibits dilated cardiomyopathy  and heart failure via up regulation of its target gene, 10/January/2017, 9.43 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

Comments are closed.